secwatch.observer — SEC 8-K summary
======================================

Issuer:     ADIAL PHARMACEUTICALS, INC. (ADIL)
CIK:        0001513525
Form:       8-K
Filed at:   2023-09-21T23:59:59+00:00
Accession:  0001213900-23-078339
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.65
Item codes: 1.01, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Adial finalizes Purnovate asset sale to Adovate; director Stilley resigns
-------------------------------------------------------------------------

- Final acquisition agreement with Adovate for Purnovate assets effective June 30, 2023.
- Reimbursable expenses of $1.05M: $350K paid June 30, $350K paid Sept 20, $350K due by Dec 2, 2023.
- Adial receives 3.46M Class A units (15% equity) in Adovate with anti-dilution until $4M cumulative funding.
- Potential milestone payments per compound (development, approval, commercial) and royalties on net sales; amounts redacted.
- Board member William B. Stilley resigned effective Sept 18, 2023, not related to any disagreement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1513525/000121390023078339/0001213900-23-078339-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1513525/000121390023078339/ea185524-8k_adialpharma.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-078339

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer